News stories about Quanterix (NASDAQ:QTRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quanterix earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7715184989344 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Anticipate Quanterix Corp (QTRX) to Announce -$0.30 Earnings Per Share (americanbankingnews.com)
- New Research Demonstrates Enhanced Sensitivity for Acute HIV Detection Using Quanterix’ Simoa Technology (it.tmcnet.com)
- Quanterix (QTRX) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com)
- $6.54 Million in Sales Expected for Quanterix Corp (QTRX) This Quarter (americanbankingnews.com)
A number of research analysts have commented on the company. Leerink Swann assumed coverage on Quanterix in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $27.00 price objective on the stock. BTIG Research began coverage on Quanterix in a research note on Tuesday, January 2nd. They issued a “buy” rating and a $26.00 price target on the stock. Cowen began coverage on Quanterix in a research note on Tuesday, January 2nd. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Quanterix in a research note on Tuesday, January 2nd. They issued an “overweight” rating on the stock.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Quanterix (QTRX) Stock Price” was posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-quanterix-qtrx-stock-price/2028514.html.
Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.